WallStSmart

Hecla Mining Company (HL)vsVersamet Royalties Corporation Common Stock (VMET)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

Hecla Mining Company generates 2251% more annual revenue ($1.74B vs $74.18M). VMET leads profitability with a 49.9% profit margin vs 19.2%. HL trades at a lower P/E of 19.9x. HL earns a higher WallStSmart Score of 73/100 (B).

HL

Strong Buy

73

out of 100

Grade: B

Growth: 10.0Profit: 8.5Value: 6.0Quality: 9.0
Piotroski: 6/9Altman Z: 2.55

VMET

Buy

60

out of 100

Grade: C+

Growth: 10.0Profit: 8.0Value: 5.3Quality: 4.5
Piotroski: 5/9Altman Z: 1.19
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

HLUndervalued (+39.4%)

Margin of Safety

+39.4%

Fair Value

$24.32

Current Price

$14.74

$9.58 discount

UndervaluedFair: $24.32Overvalued

Intrinsic value data unavailable for VMET.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

HL4 strengths · Avg: 10.0/10
Operating MarginProfitability
44.3%10/10

Strong operational efficiency at 44.3%

Revenue GrowthGrowth
52.4%10/10

Revenue surging 52.4% year-over-year

EPS GrowthGrowth
92.9%10/10

Earnings expanding 92.9% YoY

Debt/EquityHealth
0.0010/10

Conservative balance sheet, low leverage

VMET5 strengths · Avg: 9.6/10
Profit MarginProfitability
49.9%10/10

Keeps 50 of every $100 in revenue as profit

Operating MarginProfitability
58.0%10/10

Strong operational efficiency at 58.0%

Revenue GrowthGrowth
391.9%10/10

Revenue surging 391.9% year-over-year

EPS GrowthGrowth
2123.0%10/10

Earnings expanding 2123.0% YoY

Price/BookValuation
2.5x8/10

Reasonable price relative to book value

Areas to Watch

HL1 concerns · Avg: 2.0/10
PEG RatioValuation
5.642/10

Expensive relative to growth rate

VMET2 concerns · Avg: 2.5/10
Market CapQuality
$926.14M3/10

Smaller company, higher risk/reward

Altman Z-ScoreHealth
1.192/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : HL

The strongest argument for HL centers on Operating Margin, Revenue Growth, EPS Growth. Profitability is solid with margins at 19.2% and operating margin at 44.3%. Revenue growth of 52.4% demonstrates continued momentum.

Bull Case : VMET

The strongest argument for VMET centers on Profit Margin, Operating Margin, Revenue Growth. Profitability is solid with margins at 49.9% and operating margin at 58.0%. Revenue growth of 391.9% demonstrates continued momentum.

Bear Case : HL

The primary concerns for HL are PEG Ratio.

Bear Case : VMET

The primary concerns for VMET are Market Cap, Altman Z-Score.

Key Dynamics to Monitor

VMET is growing revenue faster at 391.9% — sustainability is the question.

HL generates stronger free cash flow (151M), providing more financial flexibility.

Monitor OTHER PRECIOUS METALS & MINING industry trends, competitive dynamics, and regulatory changes.

Bottom Line

HL scores higher overall (73/100 vs 60/100), backed by strong 19.2% margins and 52.4% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Hecla Mining Company

BASIC MATERIALS · OTHER PRECIOUS METALS & MINING · USA

Hecla Mining Company discovers, acquires, develops and produces precious and base metal properties in the United States and internationally. The company is headquartered in Coeur d'Alene, Idaho.

Versamet Royalties Corporation Common Stock

BASIC MATERIALS · OTHER PRECIOUS METALS & MINING · USA

Viamet Pharmaceuticals Corp (VMET) is an innovative biopharmaceutical company dedicated to the development of advanced therapeutics targeting serious diseases, particularly in the areas of fungal infections and oncology, utilizing its proprietary metalloenzyme-based technology platform. With a robust and diversified clinical pipeline supported by strategic partnerships and a comprehensive intellectual property portfolio, Viamet is strategically positioned for significant growth. The company remains focused on addressing critical unmet medical needs and is committed to enhancing shareholder value through continued therapeutic advancements in its specialized areas.

Want to dig deeper into these stocks?